431-P: Effects of CB1 Antagonist INV-202 in Patients with Metabolic Syndrome—A Randomized, Placebo-Controlled, Double-Blind Phase 1B Study

Cannabinoid blockers have been successful for the treatment of obesity. However, due to CNS side effects drug development programs were halted. We present data from INV-202, a peripherally acting next generation CB1 blocker with very low CNS penetration. This randomized, DB, PC, PG, 28day study (NCT...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Diabetes (New York, N.Y.) N.Y.), 2023-06, Vol.72 (Supplement_1), p.1
Hauptverfasser:	CRATER, GLENN D., RAVENELLE, FRANCOIS, LALONDE, KARINE, DESPRÉS, JEAN-PIERRE
Format:	Artikel
Sprache:	eng
Schlagworte:	Appetite loss Biomarkers Body weight loss Cannabinoid CB1 receptors Diarrhea Drug development Glucose tolerance Metabolic syndrome Placebos
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!